NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/07/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization72.96 mln
Float46.38 mln
Earnings Date08/12/2026
EPS
0.27
Marginal
P / E
4.67
Deeply undervalued
Piotroski F-Score
6
/ 9
Solid
Beneish M-Score
-1.4
Manipulation likely
Relative Strength
72
/ 100
Outperforming
Debt / Equity
0.05
Debt-free
Business Description
Founded in 2013 and based in Cambridge, Massachusetts, Spero Therapeutics is a clinical-stage company working to develop new medicines for bacterial infections that no longer respond to standard antibiotics, as well as certain rare conditions. Its two leading drug candidates are tebipenem HBr, an oral antibiotic for urinary tract infections currently in late-stage trials, and SPR720, an early treatment option for a serious lung disease caused by nontuberculous mycobacteria. The company works alongside partners including Meiji Seika Pharma, Everest Medicines, and Vertex Pharmaceuticals to advance its pipeline.
